---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-039716"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T13:28:18.147063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE reports positive preclinical RA data for pan-BET inhibitor VYN201; on track for H2 2022 Ph1

## Summary
- VYN201 intra-articular injection showed statistically significant inhibition of paw thickening at 1 and 10 mg/kg (p<0.01).
- At 1 mg/kg, paw thickness reduced 26.8% vs untreated; at 10 mg/kg, reduced 37.6%.
- Arthritis scores at 1 and 10 mg/kg were near normal (0.57 and 0.67), reductions of 76.5% and 79.9%.
- VYN201 numerically superior to intra-articular dexamethasone in both endpoints.
- Company confirms timeline to initiate first-in-human trial for VYN201 in second half of 2022.

## SEC filing metadata
- accession: 0001104659-22-039716
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922039716/0001104659-22-039716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922039716/tm228420d6_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-039716
- JSON: https://secwatch.observer/filing/0001104659-22-039716.json
- Plain text: https://secwatch.observer/filing/0001104659-22-039716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.